Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children

Antiviral Therapy

Volumn 9, Issue 2, 2004, Pages 297-299

  La Fraaij, Pieter ^a,b   Neubert, Jennifer ^b   Bergshoeff, Alina S ^c   Van Rossum, Annemarie M C ^a   Hartwig, Nico G ^a   Schroten, Horst ^b   Korn, Klaus ^d   Burger, David M ^c   De Groot, Ronald ^a   Niehues, Tim ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Institute of Virology Erlangen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; VIRUS DNA;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIRUS LOAD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; OXAZINES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME;

EID: 2342441341     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Saez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E, Pelton S, Ramilo O, Cahn P, Chadwick E, Allen U, Arpadi S, Castrejon MM, Heuser RS, Kempf DJ, Bertz RJ, Hsu AF, Bernstein B, Renz CL & Sun E. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatric Infectious Diseases 2003; 22(3):216-224.
2. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM & Flynn PM. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. New England Journal of Medicine 1999; 341(25):1874-1881.